<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:de25d40e-38da-4a98-8077-955a1047221d,g:5810c129-1b48-4328-aa5a-1dd4fa6ea06d,d:e6e4157019eb41859c04ad401900c521--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvax-20230509</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl8zLTEtMS0xLTE0ODM5NA_2335efb7-91ee-4be5-a9cc-c8e5329a0cc6">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV80L2ZyYWc6NTdhZjQyMjQ5Njk2NDAzZTg1YWRmYmNhMWI0Mzg3ZjcvdGFibGU6OTg1NzExNmQ2MDlhNGUwYWFkYWMzN2E1MDM0YTgyNWIvdGFibGVyYW5nZTo5ODU3MTE2ZDYwOWE0ZTBhYWRhYzM3YTUwMzRhODI1Yl80LTEtMS0xLTE0ODM5NA_0fbea106-d533-41cd-9bbc-2fb1a9a77d1a">0001000694</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvax-20230509.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001000694</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie6e4157019eb41859c04ad401900c521_1"></div><div style="min-height:18pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk4_466896ef-8fe3-4dc7-80ed-981ff32262bf">8-K</ix:nonNumeric></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:100%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8yNDU_6cd27995-3335-4fb6-91f9-72c1766b5f0b">May 9, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk5_9b5538d5-6d52-4d81-9388-eb0c465324f5">NOVAVAX, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in charter) </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTAtMS0xLTE0ODM5NA_53645ee9-6b08-4ca6-b67b-903545690b9a">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTItMS0xLTE0ODM5NA_7f34f4cf-7bcb-452b-b2d7-1097c9e6f963">0-26770</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDM1OThkZDhhYjJhNDUxM2EyZTYwMGY0MGMzNDM5YmQvdGFibGVyYW5nZTpkMzU5OGRkOGFiMmE0NTEzYTJlNjAwZjQwYzM0MzliZF8wLTQtMS0xLTE0ODM5NA_09f2fce9-2cec-4fd9-98a1-0eaeee9e028a">22-2816046</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAx_6855de82-4922-487f-bb3e-84caff55ffeb">21 Firstfield Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk0_742e7f15-74d7-4eb1-8ee3-64ece08b8c73">Gaithersburg</ix:nonNumeric>, <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk1_11bd4b23-4ab2-4e56-841e-eecb4c82d390">Maryland</ix:nonNumeric> <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8zNzI_7d55f9d9-43cc-4a72-885d-566412adc85a">20878</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk2_205991c5-ac9e-40cd-9ce0-2e46ecc681fa">(240)</ix:nonNumeric> <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xMzk3_4b884a47-1a10-467c-b6c3-5538cd503ef5">268-2000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Former name or former address, if changed since last report.) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6Y2I5MDFjZTkwNzY1NDY1M2JhZGY0MWRkYjkxMWY4MWQvdGFibGVyYW5nZTpjYjkwMWNlOTA3NjU0NjUzYmFkZjQxZGRiOTExZjgxZF8wLTEtMS0xLTE0ODM5NA_e9897799-cae0-4034-91c9-094c14857ff0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6NDFlODcwOWE3NGQzNDIwZjg3OTYzMjZjZTIwMTNhMjAvdGFibGVyYW5nZTo0MWU4NzA5YTc0ZDM0MjBmODc5NjMyNmNlMjAxM2EyMF8wLTEtMS0xLTE0ODM5NA_57e0ebd5-f214-4799-933c-7387842a7954">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ZDFjY2NiMmJjZjRkNDNkMTlmOTY4MGE4YjQ5NDhkMzEvdGFibGVyYW5nZTpkMWNjY2IyYmNmNGQ0M2QxOWY5NjgwYThiNDk0OGQzMV8wLTEtMS0xLTE0ODM5NA_405744b3-54e4-4113-afb6-6a75989385a8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.700%"><tr><td style="width:0.1%"></td><td style="width:0.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6MjFhYjNlYzRlYzg5NGVmOTkwYjg3NGE4MzJlZTgwN2IvdGFibGVyYW5nZToyMWFiM2VjNGVjODk0ZWY5OTBiODc0YTgzMmVlODA3Yl8wLTEtMS0xLTE0ODM5NA_623d3b95-f98f-4b1c-8eee-76ecaa76b6f6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:40.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading <br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which <br/>registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTAtMS0xLTE0ODM5NA_53d81008-3090-4101-b620-3a03d6ee3516">Common Stock, Par Value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTItMS0xLTE0ODM5NA_8388de94-b990-4078-b4a9-3bea1e1e921b">NVAX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGFibGU6ODEzMzdiOTA4ZTVkNDUyNWE0NzE3MjcyYzIzZmZlYTkvdGFibGVyYW5nZTo4MTMzN2I5MDhlNWQ0NTI1YTQ3MTcyNzJjMjNmZmVhOV8xLTQtMS0xLTE0ODM5NA_1ac6a8ab-414d-4be9-bace-6f9badedb7f5">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="padding-left:216pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:216pt;text-indent:-216pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i67b9990c6e344e30bec5eb7a75b3b771_D20230509-20230509" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmU2ZTQxNTcwMTllYjQxODU5YzA0YWQ0MDE5MDBjNTIxL3NlYzplNmU0MTU3MDE5ZWI0MTg1OWMwNGFkNDAxOTAwYzUyMV8xL2ZyYWc6MTQ1NGNlYTY4MTQxNDAwODhhNzVhYmRkNGIwYmQzNTQvdGV4dHJlZ2lvbjoxNDU0Y2VhNjgxNDE0MDA4OGE3NWFiZGQ0YjBiZDM1NF8xNDAz_980acec5-ebf2-4c80-9355-944d6097041b">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie6e4157019eb41859c04ad401900c521_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">First Quarter Financial Results</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 9, 2023, Novavax, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended March 31, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div id="ie6e4157019eb41859c04ad401900c521_122"></div><div><span><br/></span></div><div><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.05. Costs Associated with Exit or Disposal Activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As previously announced, a near-term priority for the Company includes reducing its annual combined research and development and selling, general and administrative spend.  In connection with those plans, on May 8, 2023, the Board of Directors of the Company approved an approximately 25% reduction of its global workforce, comprised of an approximately 20% reduction in the Company&#8217;s full-time employees and the remainder comprised of contractors and consultants.  The Company expects the full annual impact of the cost savings to be realized in 2024 and approximately half of the annual impact, excluding one-time charges, to be realized in 2023 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which it operates.  The Company is expected to record a charge of approximately $10 million to $15 million related one-time employee severance and benefit costs, the majority of which is expected to be incurred in the second quarter of 2023 and it is evaluating the anticipated cost related to the consolidation of facilities and infrastructure.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div id="ie6e4157019eb41859c04ad401900c521_130"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 7.01. Regulation FD Disclosure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On May 9, 2023, the Company issued a press release announcing results of the Company&#8217;s Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information in Items 2.02, 7.01 and 9.01 of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Current Report on Form 8-K includes forward-looking statements including the Company&#8217;s priorities, the size and timing of the Company&#8217;s workforce reduction, the amount and timing of the charges and cash expenditures resulting from the workforce reduction, and the expected timing and impact of cost savings from the global restructuring and cost reduction plan. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Generally, forward-looking statements can be identified through the use of words or phrases such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;possible,&#8221; &#8220;can,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;consider,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;aim,&#8221; or &#8220;assume,&#8221; the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.  Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements.&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Such risks and uncertainties include, among others, that the workforce reduction may be larger than currently anticipated, the Company may incur additional costs not currently contemplated, and other risks and uncertainties are identified under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Report on Form 10-K and in any subsequent filings with the Securities and Exchange Commission.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Further, any forward-looking statement speaks only as of the date when it is made, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for the Company to predict which factors will arise. In addition, the Company cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie6e4157019eb41859c04ad401900c521_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01. Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.276%"><tr><td style="width:1.0%"></td><td style="width:9.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">Press release, dated May 9, 2023, regarding the Company&#8217;s financial results for the quarter ended March&#160;31</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">, 2023</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q23earningspressrelease_.htm">.</a></span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cicpressrelease_final.htm">99.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cicpressrelease_final.htm">Press release, dated May 9, 2023, regarding results of the Company&#8217;s Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL).</span></td></tr></table></div><div id="ie6e4157019eb41859c04ad401900c521_13"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.418%"><tr><td style="width:1.0%"></td><td style="width:47.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOVAVAX, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John A. Herrmann III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John A. Herrmann III</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Legal Officer and Corporate Secretary</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "nvax-20230509.htm", "description": "8-K", "secsgml_size_bytes": 52628}]
{"company-data": {"conformed-name": "NOVAVAX INC", "cik": "0001000694", "assigned-sic": "2836", "irs-number": "222816046", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26770", "film-number": "23900037"}, "business-address": {"street1": "21 FIRSTFIELD ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "240-268-2000"}, "mail-address": {"street1": "21 FIRSTFIELD ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
nvax-20230509
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 9, 2023
NOVAVAX, INC
.
(Exact name of registrant as specified in charter)
Delaware
0-26770
22-2816046
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
21 Firstfield Road
Gaithersburg
,
Maryland
20878
(Address of Principal Executive Offices, including Zip Code)
(240)
268-2000
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which
registered
Common Stock, Par Value $0.01 per share
NVAX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
First Quarter Financial Results
On May 9, 2023, Novavax, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended March 31, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 2.05. Costs Associated with Exit or Disposal Activities.
As previously announced, a near-term priority for the Company includes reducing its annual combined research and development and selling, general and administrative spend.  In connection with those plans, on May 8, 2023, the Board of Directors of the Company approved an approximately 25% reduction of its global workforce, comprised of an approximately 20% reduction in the Company's full-time employees and the remainder comprised of contractors and consultants.  The Company expects the full annual impact of the cost savings to be realized in 2024 and approximately half of the annual impact, excluding one-time charges, to be realized in 2023 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which it operates.  The Company is expected to record a charge of approximately $10 million to $15 million related one-time employee severance and benefit costs, the majority of which is expected to be incurred in the second quarter of 2023 and it is evaluating the anticipated cost related to the consolidation of facilities and infrastructure.
Item 7.01. Regulation FD Disclosure.
On May 9, 2023, the Company issued a press release announcing results of the Company's Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines. A copy of this press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Items 2.02, 7.01 and 9.01 of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such a filing.
This Current Report on Form 8-K includes forward-looking statements including the Company's priorities, the size and timing of the Company's workforce reduction, the amount and timing of the charges and cash expenditures resulting from the workforce reduction, and the expected timing and impact of cost savings from the global restructuring and cost reduction plan.
Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "could," "will," "would," "possible," "can," "estimate," "continue," "ongoing," "consider," "anticipate," "intend," "seek," "plan," "project," "expect," "should," "would," "aim," or "assume," the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.  Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, and, therefore, you should not place considerable reliance on any such forward-looking statements.
Such risks and uncertainties include, among others, that the workforce reduction may be larger than currently anticipated, the Company may incur additional costs not currently contemplated, and other risks and uncertainties are identified under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in any subsequent filings with the Securities and Exchange Commission.
Further, any forward-looking statement speaks only as of the date when it is made, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. New factors emerge from time to time, and it is not possible for the Company to predict which factors will arise. In addition, the Company cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
Description
99.1
Press release, dated May 9, 2023, regarding the Company's financial results for the quarter ended March 31
, 2023
.
99.2
Press release, dated May 9, 2023, regarding results of the Company's Phase 2 clinical trial for combination COVID-influenza, standalone influenza, and high-dose COVID vaccines.
104
Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NOVAVAX, INC.
Date: May 9, 2023
By:
/s/ John A. Herrmann III
Name:
John A. Herrmann III
Title:
Executive Vice President, Chief Legal Officer and Corporate Secretary